These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27119769)

  • 41. Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
    Agrawal AK; Feusner JH
    Br J Haematol; 2011 Apr; 153(2):275-7. PubMed ID: 21255003
    [No Abstract]   [Full Text] [Related]  

  • 42. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rasburicase in cancer-related hyperuricemia.
    Rodriguez M; Campara M; Haaf C
    Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advanced germ cell tumors and chemotherapy in G6PD deficient patients: Yes to chemotherapy but no to rasburicase and some premedications.
    Gazouli I; Baltogiannis D; Ntellas P; Smaragdi Vlachou M; Tagkas C; Champilomatis I; Kampletsas Ε; Tolia M; Mauri D
    J BUON; 2021; 26(4):1642-1646. PubMed ID: 34565030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemolytic anemia after methylene blue therapy for aniline-induced methemoglobinemia.
    Liao YP; Hung DZ; Yang DY
    Vet Hum Toxicol; 2002 Feb; 44(1):19-21. PubMed ID: 11824767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rasburicase in the prevention and treatment of tumour lysis syndrome.
    Mayne N; Keady S; Thacker M
    Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
    Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of tumor lysis syndrome in adults.
    Coiffier B; Riouffol C
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):233-9. PubMed ID: 17288532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Central Nervous System Symptoms Due to Transient Methemoglobinemia in a Child With G6PD Deficiency.
    Sharma S; Srinivasaraghavan R; Krishnamurthy S
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):e27-e28. PubMed ID: 27879542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renal tubular damage in rasburicase: risks of alkalinisation.
    van den Berg H; Reintsema AM
    Ann Oncol; 2004 Jan; 15(1):175-6. PubMed ID: 14679140
    [No Abstract]   [Full Text] [Related]  

  • 51. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
    Goldman SC
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):429-33. PubMed ID: 12934655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient.
    Bhat P; Sisler I; Collier AB
    Pediatr Blood Cancer; 2008 Oct; 51(4):568. PubMed ID: 18561168
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metoclopramide-induced methemoglobinemia in a patient with co-existing deficiency of glucose-6-phosphate dehydrogenase and NADH-cytochrome b5 reductase: failure of methylene blue treatment.
    Karadsheh NS; Shaker Q; Ratroat B
    Haematologica; 2001 Jun; 86(6):659-60. PubMed ID: 11418378
    [No Abstract]   [Full Text] [Related]  

  • 55. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
    Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
    Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Acute drug-induced hemolytic anemia associated with met- and sulfhemoglobinemia (glucose-6-phosphate dehydrogenase deficiency in the erythrocytes)].
    Kushakovskiĭ MS
    Probl Gematol Pereliv Krovi; 1966 Jun; 11(6):59-63. PubMed ID: 5990681
    [No Abstract]   [Full Text] [Related]  

  • 58. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Things We Do for No Reason™: Rasburicase for Adult Patients With Tumor Lysis Syndrome.
    Niforatos JD; Zheutlin AR; Chaitoff A; Hilal T
    J Hosp Med; 2021 Jul; 16(7):424-427. PubMed ID: 34197308
    [No Abstract]   [Full Text] [Related]  

  • 60. Methemoglobinemia and intravascular hemolysis in a patient with G6PD deficiency.
    Finielz P; Gendoo Z; Lataste A; Chuet C; Guiserix J
    Nephron; 1992; 62(2):242. PubMed ID: 1436328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.